After finishing at $24.25 in the prior trading day, Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) closed at $23.73, down -2.14%. In other words, the price has decreased by -$0.52 from its previous closing price. On the day, 458219 shares were traded.
Ratios:
Our goal is to gain a better understanding of BCYC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.08 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
On July 28, 2022, Barclays started tracking the stock assigning a Overweight rating and target price of $30.Barclays initiated its Overweight rating on July 28, 2022, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 03 ’24 when Lee Kevin sold 8,703 shares for $17.50 per share. The transaction valued at 152,302 led to the insider holds 390,428 shares of the business.
Crockett Nigel sold 2,643 shares of BCYC for $46,252 on Jan 03 ’24. The Chief Business Officer now owns 48,716 shares after completing the transaction at $17.50 per share. On Jan 03 ’24, another insider, Skynner Michael, who serves as the Chief Technology Officer of the company, sold 2,643 shares for $17.50 each. As a result, the insider received 46,252 and left with 95,839 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCYC now has a Market Capitalization of 898.14M and an Enterprise Value of 416.67M. For the stock, the TTM Price-to-Sale (P/S) ratio is 37.19 while its Price-to-Book (P/B) ratio in mrq is 2.71. Its current Enterprise Value per Revenue stands at 15.45 whereas that against EBITDA is -2.46.
Stock Price History:
Over the past 52 weeks, BCYC has reached a high of $28.91, while it has fallen to a 52-week low of $12.54. The 50-Day Moving Average of the stock is 22.40, while the 200-Day Moving Average is calculated to be 20.33.
Shares Statistics:
The stock has traded on average 361.89K shares per day over the past 3-months and 405.07k shares per day over the last 10 days, according to various share statistics. A total of 42.43M shares are outstanding, with a floating share count of 41.93M. Insiders hold about 1.19% of the company’s shares, while institutions hold 76.03% stake in the company. Shares short for BCYC as of Mar 15, 2024 were 2.56M with a Short Ratio of 7.06, compared to 3.39M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.75% and a Short% of Float of 6.83%.
Earnings Estimates
Its stock is currently analyzed by 11 different market analysts. On average, analysts expect EPS of -$1.24 for the current quarter, with a high estimate of -$1.03 and a low estimate of -$1.4, while EPS last year was -$1.3. The consensus estimate for the next quarter is -$1.3, with high estimates of -$1.12 and low estimates of -$1.51.
Analysts are recommending an EPS of between -$4.43 and -$5.9 for the fiscal current year, implying an average EPS of -$5.18. EPS for the following year is -$5.52, with 12 analysts recommending between -$4.59 and -$7.05.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for BCYC’s current fiscal year. The highest revenue estimate was $53.4M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $27.48M. In the same quarter a year ago, actual revenue was $26.98M, up 1.90% from the average estimate.
